% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Savary:127445,
author = {C. C. Savary and X. Jiang$^*$ and M. Aubry and R. Jossé
and A. Kopp-Schneider$^*$ and P. Hewitt and A. Guillouzo},
title = {{T}ranscriptomic analysis of untreated and drug-treated
differentiated {H}epa{RG} cells over a 2-week period.},
journal = {Toxicology in vitro},
volume = {30},
number = {1 Pt A},
issn = {0887-2333},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2017-03468},
pages = {27 - 35},
year = {2015},
abstract = {Previous works have shown that differentiated human HepaRG
cells can exhibit drug metabolism activities close to those
of primary human hepatocytes for several weeks at
confluence. The present study was designed to evaluate their
long-term functional stability and their response to
repeated daily drug treatments over a 14-day period, using a
transcriptomic approach. Our data show that less than $1\%$
of the expressed genes were markedly deregulated over this
two weeks period and mainly included down-regulation of
genes related to the cell cycle and from 3 days,
overexpression of genes involved in xenobiotic and lipid
metabolism. After daily treatment with the three PPAR
agonists, fenofibrate, troglitazone and rosiglitazone
qualitative and/or quantitative changes in gene profiling
were observed depending on the compound and duration of
treatment. The highest increase in the number of deregulated
genes as a function of drug treatment was seen with
rosiglitazone. The most up-regulated genes common across the
three compounds were mainly related to lipid and xenobiotic
metabolisms. All the data support the conclusion that human
HepaRG cells have an exceptional functional stability at
confluence and that they are suitable for investigations on
chronic effects of drugs and other chemicals.},
keywords = {Chromans (NLM Chemicals) / Hypoglycemic Agents (NLM
Chemicals) / Hypolipidemic Agents (NLM Chemicals) /
Peroxisome Proliferator-Activated Receptors (NLM Chemicals)
/ Thiazolidinediones (NLM Chemicals) / rosiglitazone (NLM
Chemicals) / troglitazone (NLM Chemicals) / Fenofibrate (NLM
Chemicals)},
cin = {C060},
ddc = {610},
cid = {I:(DE-He78)C060-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:25572481},
doi = {10.1016/j.tiv.2014.12.019},
url = {https://inrepo02.dkfz.de/record/127445},
}